Clinical Trials Browser

Phase 2/3 × Palonosetron × Clear all

NCT03040726 2023-10-17

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Phase 2/3 Completed

53 enrolled 15 charts

Nausea, Neoplasms, Vomiting

NCT03606369 2018-07-30

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

Phase 2/3 Unknown

Breast Neoplasms